Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.49 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | MLNR | O43193 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17339944 | 0.92 | SLC6A2 (0.54) | SLC6A2SLC6A4SLC6A3KMT2ASMN1; SMN2 | |
| SCHEMBL10260953 | 0.92 | SLC6A2 (0.54) | SLC6A2SLC6A4SLC6A3KMT2ASMN1; SMN2 | |
| SCHEMBL7235082 | 0.84 | SLC6A2 (0.67) | SLC6A2SLC6A4SLC6A3KMT2ASMN1; SMN2 | |
| SCHEMBL17123796 | 0.83 | SLC6A4 (0.54) | SLC6A2SLC6A4SLC6A3KMT2AHRH3 | |
| SCHEMBL10057699 | 0.83 | HRH3 (0.53) | SLC6A2SLC6A4SLC6A3SMN1; SMN2HRH3 | |
| SCHEMBL13855678 | 0.83 | SLC6A2 (0.51) | SLC6A2SLC6A4SLC6A3KMT2ASMN1; SMN2 | |
| SCHEMBL6124978 | 0.83 | HRH3 (0.50) | KMT2ASMN1; SMN2HRH3MAOAMAOB | |
| SCHEMBL374287 | 0.82 | HRH3 (0.50) | SLC6A2SLC6A3SMN1; SMN2HRH3MAOA | |
| SCHEMBL12677068 | 0.82 | SLC6A2 (0.56) | SLC6A2SLC6A4SLC6A3SMN1; SMN2HRH3 | |
| SCHEMBL5540295 | 0.82 | SLC6A2 (0.56) | SLC6A2SLC6A4SLC6A3KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11648243-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-8148404-B2 | Modulators of CB1 receptors | 7TM PHARMA A/S (DK) | 2012-04-03 | — | — | US | disclosed |
| US-20100144701-A1 | Modulators of CB1 Receptors | 7TM PHARMA A/S (DK) | 2010-06-10 | — | — | US | disclosed |
| WO-2007009236-A1 | HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11648243-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, BRAF, RAF1 | SLC6A2 4053/4885SLC6A4 3586/4885SLC6A3 1858/4885 |
| US-20100144701-A1 | Modulators of CB1 Receptors | CNR1, CNR2, GPR6 | SLC6A2 1973/4885SLC6A4 1525/4885SLC6A3 658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.